Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19
Purpose COVID-19 is characterized by dysfunctional immune responses and metabolic derangements, which in some, lead to multi-organ failure and death. Statins are foundational lipid-lowering therapeutics for cardiovascular disease and also possess beneficial immune-modulating properties. Because of t...
Saved in:
Published in | Cardiovascular drugs and therapy Vol. 36; no. 6; pp. 1165 - 1173 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Springer US
01.12.2022
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose
COVID-19 is characterized by dysfunctional immune responses and metabolic derangements, which in some, lead to multi-organ failure and death. Statins are foundational lipid-lowering therapeutics for cardiovascular disease and also possess beneficial immune-modulating properties. Because of these immune-modulating properties, some have suggested their use in COVID-19. We sought to investigate the association between statin use and mortality in patients hospitalized with COVID-19.
Methods
Five thousand three hundred seventy-five COVID-19 patients admitted to Mount Sinai Health System hospitals in New York between February 27, 2020, and December 3, 2020, were included in this analysis. Statin use was classified as either non-user, low-to-moderate-intensity user, or high-intensity user. Multivariate Cox proportional hazards models were used to evaluate in-hospital mortality rate. Considered covariates were age, sex, race, and comorbidities.
Results
Compared to non-statin users, both low-to-moderate-intensity (adjusted hazard ratio; aHR 0.62, 95% confidential intervals; CI 0.51–0.76) and high-intensity statin users (aHR 0.53, 95% CI 0.43–0.65) had a reduced risk of death. Subgroup analysis of 723 coronary artery disease patients showed decreased mortality among high-intensity statin users compared to non-users (aHR 0.51, 95% CI 0.36–0.71).
Conclusions
Statin use in patients hospitalized with COVID-19 was associated with a reduced in-hospital mortality. The protective effect of statin was greater in those with coronary artery disease. These data support continued use of statin therapy in hospitalized patients with COVID-19. Clinical trials are needed to prospectively determine if statin use is effective in lowering the mortality in COVID-19 and other viral infections. |
---|---|
AbstractList | PurposeCOVID-19 is characterized by dysfunctional immune responses and metabolic derangements, which in some, lead to multi-organ failure and death. Statins are foundational lipid-lowering therapeutics for cardiovascular disease and also possess beneficial immune-modulating properties. Because of these immune-modulating properties, some have suggested their use in COVID-19. We sought to investigate the association between statin use and mortality in patients hospitalized with COVID-19.MethodsFive thousand three hundred seventy-five COVID-19 patients admitted to Mount Sinai Health System hospitals in New York between February 27, 2020, and December 3, 2020, were included in this analysis. Statin use was classified as either non-user, low-to-moderate-intensity user, or high-intensity user. Multivariate Cox proportional hazards models were used to evaluate in-hospital mortality rate. Considered covariates were age, sex, race, and comorbidities.ResultsCompared to non-statin users, both low-to-moderate-intensity (adjusted hazard ratio; aHR 0.62, 95% confidential intervals; CI 0.51–0.76) and high-intensity statin users (aHR 0.53, 95% CI 0.43–0.65) had a reduced risk of death. Subgroup analysis of 723 coronary artery disease patients showed decreased mortality among high-intensity statin users compared to non-users (aHR 0.51, 95% CI 0.36–0.71).ConclusionsStatin use in patients hospitalized with COVID-19 was associated with a reduced in-hospital mortality. The protective effect of statin was greater in those with coronary artery disease. These data support continued use of statin therapy in hospitalized patients with COVID-19. Clinical trials are needed to prospectively determine if statin use is effective in lowering the mortality in COVID-19 and other viral infections. Purpose COVID-19 is characterized by dysfunctional immune responses and metabolic derangements, which in some, lead to multi-organ failure and death. Statins are foundational lipid-lowering therapeutics for cardiovascular disease and also possess beneficial immune-modulating properties. Because of these immune-modulating properties, some have suggested their use in COVID-19. We sought to investigate the association between statin use and mortality in patients hospitalized with COVID-19. Methods Five thousand three hundred seventy-five COVID-19 patients admitted to Mount Sinai Health System hospitals in New York between February 27, 2020, and December 3, 2020, were included in this analysis. Statin use was classified as either non-user, low-to-moderate-intensity user, or high-intensity user. Multivariate Cox proportional hazards models were used to evaluate in-hospital mortality rate. Considered covariates were age, sex, race, and comorbidities. Results Compared to non-statin users, both low-to-moderate-intensity (adjusted hazard ratio; aHR 0.62, 95% confidential intervals; CI 0.51–0.76) and high-intensity statin users (aHR 0.53, 95% CI 0.43–0.65) had a reduced risk of death. Subgroup analysis of 723 coronary artery disease patients showed decreased mortality among high-intensity statin users compared to non-users (aHR 0.51, 95% CI 0.36–0.71). Conclusions Statin use in patients hospitalized with COVID-19 was associated with a reduced in-hospital mortality. The protective effect of statin was greater in those with coronary artery disease. These data support continued use of statin therapy in hospitalized patients with COVID-19. Clinical trials are needed to prospectively determine if statin use is effective in lowering the mortality in COVID-19 and other viral infections. |
Author | Smith, Robin L. Rosenson, Robert S. Mejia, Priscilla Choi, Daein Pacheco, Hannah Chen, Qinzhong Goonewardena, Sascha N. |
Author_xml | – sequence: 1 givenname: Daein surname: Choi fullname: Choi, Daein organization: Department of Medicine, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai – sequence: 2 givenname: Qinzhong surname: Chen fullname: Chen, Qinzhong organization: Metabolism and Lipids Unit, Cardiovascular Institute, Marie-Josee and Henry R Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, The Mount Sinai Medical Center – sequence: 3 givenname: Sascha N. surname: Goonewardena fullname: Goonewardena, Sascha N. organization: Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan – sequence: 4 givenname: Hannah surname: Pacheco fullname: Pacheco, Hannah organization: Metabolism and Lipids Unit, Cardiovascular Institute, Marie-Josee and Henry R Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, The Mount Sinai Medical Center – sequence: 5 givenname: Priscilla surname: Mejia fullname: Mejia, Priscilla organization: Metabolism and Lipids Unit, Cardiovascular Institute, Marie-Josee and Henry R Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, The Mount Sinai Medical Center – sequence: 6 givenname: Robin L. surname: Smith fullname: Smith, Robin L. organization: Clinical Associate Professor, Department of Medicine, Rutgers New Jersey Medical School and the CURA Foundation – sequence: 7 givenname: Robert S. surname: Rosenson fullname: Rosenson, Robert S. email: robert.rosenson@mssm.edu organization: Metabolism and Lipids Unit, Cardiovascular Institute, Marie-Josee and Henry R Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, The Mount Sinai Medical Center |
BookMark | eNp9kUFvVCEUhYlpY6ejf8AViRs3KFzgMWxMmmm1jU3axOqW8HjQoXkDI7zRzL-XcRqNXXQF4Z7z5VzOKTpKOXmE3jD6nlGqPlRGpVSEAiNUQccJvEAzJhUnCgQ7QjOqgRIOtDtBp7U-0GbSevESnXAhQcium6EvFyFEZ90O54C_TnaKCd-tfLGbHW7X2_bg01Txrzit8GWumzjZEZ8N61hrzAmHXPDy5vvVOWH6FToOdqz-9eM5R98-XdwtL8n1zeer5dk1cYLCRAQLXc-C7mEhmOhdF6h1wHUYtBe9UmFwFrgAp3qpehqY12zgegjSMqEWks_RxwN3s-3XfnAtYLGj2ZS4tmVnso3m_0mKK3Off5qFEFTxPeDdI6DkH1tfJ9PWcX4cbfJ5Ww1IBbolaH86R2-fSB_ytqS2noGGEowD26vgoHIl11p8-BuGUbPvyhy6Mq0r86crA83ED6baxOnel3_oZ1y_AUdOlko |
Cites_doi | 10.1016/j.amjcard.2020.08.004 10.1161/JAHA.120.018475 10.1016/j.amjcard.2020.09.012 10.1016/j.jacc.2013.07.036 10.1055/s-0040-1713152 10.1111/imm.12902 10.1378/chest.06-1997 10.1056/NEJMoa1403285 10.3390/jpm11020116 10.1016/j.dsx.2020.08.023 10.1001/jama.2012.96867 10.1016/j.jacc.2020.08.058 10.1038/s41467-021-21553-1 10.1371/journal.pone.0254635 10.1038/nature02145 10.1056/NEJMoa2004500 10.1016/j.cell.2020.02.052 10.1056/NEJMoa0807646 10.1038/s41598-020-77131-w 10.1128/mBio.01120-15 10.1093/infdis/jir695 10.1016/j.bcp.2014.11.013 10.1136/bmjopen-2020-044421 10.1016/j.jacc.2017.07.752 10.21037/jlpm-20-98 10.1001/jamacardio.2020.0950 10.1016/j.jacl.2021.03.002 10.1161/CIRCRESAHA.116.308537 10.1016/j.biopha.2016.04.043 10.1007/s00380-016-0936-5 10.1016/j.jamda.2020.06.018 10.1016/j.cmet.2020.06.015 10.2147/PPA.S40736 10.1016/j.jacc.2020.08.059 10.1016/j.jacc.2019.09.025 10.1016/j.numecd.2021.02.020 10.1128/mBio.00638-15 10.1016/j.ijid.2020.03.017 10.1016/S0140-6736(20)30566-3 10.1136/postgradmedj-2020-139172 |
ContentType | Journal Article |
Copyright | Springer Science+Business Media, LLC, part of Springer Nature 2021 Springer Science+Business Media, LLC, part of Springer Nature 2021. |
Copyright_xml | – notice: Springer Science+Business Media, LLC, part of Springer Nature 2021 – notice: Springer Science+Business Media, LLC, part of Springer Nature 2021. |
DBID | AAYXX CITATION 3V. 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FR3 FYUFA GHDGH K9. M0S M1P M7Z P64 PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1007/s10557-021-07263-2 |
DatabaseName | CrossRef ProQuest Central (Corporate) ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central AUTh Library subscriptions: ProQuest Central ProQuest One Community College Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biochemistry Abstracts 1 Biotechnology and BioEngineering Abstracts ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef Technology Research Database ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Biochemistry Abstracts 1 Engineering Research Database ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Technology Research Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1573-7241 |
EndPage | 1173 |
ExternalDocumentID | 10_1007_s10557_021_07263_2 |
GrantInformation_xml | – fundername: cura foundation – fundername: ; |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 7X7 88E 8AO 8FI 8FJ 8FW 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKAS AAKSU AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZCM ADZKW AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFEXP AFKRA AFLOW AFNRJ AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAK LLZTM LSO M1P M4Y MA- N2Q NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK8 YFH YLTOR Z45 Z7U Z82 Z87 Z8O Z8V Z91 ZGI ZMTXR ZOVNA ~EX AACDK AAEOY AAJBT AASML AAYXX ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF ALIPV CITATION H13 7XB 8FD 8FK FR3 K9. M7Z P64 PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c402t-41f6b1f9b28414bc6f0ac239fd9e4b77fdca2342c7b57b0f1e91d39df5a147853 |
IEDL.DBID | U2A |
ISSN | 0920-3206 |
IngestDate | Tue Sep 17 21:19:18 EDT 2024 Fri Aug 16 07:21:51 EDT 2024 Thu Oct 10 22:50:07 EDT 2024 Thu Sep 12 18:11:44 EDT 2024 Sat Dec 16 12:06:47 EST 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | COVID-19 Statin Coronary artery disease Mortality |
Language | English |
License | This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c402t-41f6b1f9b28414bc6f0ac239fd9e4b77fdca2342c7b57b0f1e91d39df5a147853 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8440735 |
PMID | 34524566 |
PQID | 2735413216 |
PQPubID | 36270 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8440735 proquest_miscellaneous_2572934226 proquest_journals_2735413216 crossref_primary_10_1007_s10557_021_07263_2 springer_journals_10_1007_s10557_021_07263_2 |
PublicationCentury | 2000 |
PublicationDate | 2022-12-01 |
PublicationDateYYYYMMDD | 2022-12-01 |
PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York – name: Dordrecht |
PublicationTitle | Cardiovascular drugs and therapy |
PublicationTitleAbbrev | Cardiovasc Drugs Ther |
PublicationYear | 2022 |
Publisher | Springer US Springer Nature B.V |
Publisher_xml | – name: Springer US – name: Springer Nature B.V |
References | LohiaPKapurSBenjaramSMirTAssociation between antecedent statin use and severe disease outcomes in COVID-19: a retrospective study with propensity score matchingJ Clin Lipidol20211545145910.1016/j.jacl.2021.03.002337269847936125 ZhouFYuTDuRFanGLiuYLiuZClinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyLancet2020395105410621:CAS:528:DC%2BB3cXkvVGktL8%3D10.1016/S0140-6736(20)30566-3321710767270627 TikooKPatelGKumarSKarpePASanghaviMMalekVTissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modificationsBiochem Pharmacol2015933433511:CAS:528:DC%2BC2cXitVygsLnM10.1016/j.bcp.2014.11.01325482567 Pal R, Banerjee M, Yadav U, Bhattacharjee S. Statin use and clinical outcomes in patients with COVID-19: an updated systematic review and meta-analysis. Postgrad Med J. 2021. postgradmedj-2020-139172. OhTKSongIJeonYTStatin therapy and the risk of COVID-19: a cohort study of the national health insurance service in South KoreaJ Pers Med202111211610.3390/jpm11020116335789377916713 HariyantoTIKurniawanAStatin and outcomes of coronavirus disease 2019 (covid-19): a systematic review, meta-analysis, and meta-regressionNutr Metab Cardiovasc Dis202131166216701:CAS:528:DC%2BB3MXoslyqtbg%3D10.1016/j.numecd.2021.02.020338389927910652 ShiSQinMShenBCaiYLiuTYangFAssociation of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, ChinaJAMA Cardiol2020580281010.1001/jamacardio.2020.0950322118167097841 DanielsLBRenJKumarKBuiQMZhangJZhangXRelation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: findings from the American Heart Association’s COVID-19 cardiovascular disease registryPLoS One.202116e02546351:CAS:528:DC%2BB3MXhs1Whs7jO10.1371/journal.pone.0254635342649748281996 GuptaAMadhavanMVPoteruchaTJDeFilippisEMHennesseyJARedforsBAssociation between antecedent statin use and decreased mortality in hospitalized patients with COVID-19Nat Commun20211213251:CAS:528:DC%2BB3MXltlyktro%3D10.1038/s41467-021-21553-1336377137910606 YangJZhengYGouXPuKChenZGuoQPrevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysisInt J Infect Dis20209491951:CAS:528:DC%2BB3cXnslOgsrY%3D10.1016/j.ijid.2020.03.017321735747194638 De SpiegeleerABronselaerATeoJTByttebierGDe TreGBelmansLThe effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residentsJ Am Med Dir Assoc202021909914 e90210.1016/j.jamda.2020.06.018326748187294267 BhatrajuPKGhassemiehBJNicholsMKimRJeromeKRNallaAKCOVID-19 in critically ill patients in the Seattle region - case seriesN Engl J Med2020382201220221:CAS:528:DC%2BB3cXhtVeksrbN10.1056/NEJMoa200450032227758 ChoiDChoiSKimHKimKKimNKoAImpact of continuity of care on cardiovascular disease risk among newly-diagnosed hypertension patientsSci Rep202010199911:CAS:528:DC%2BB3cXitl2nsL%2FI10.1038/s41598-020-77131-w332039317672066 RoccaforteVDavesMLippiGSpreaficoMBonatoCAltered lipid profile in patients with COVID-19 infectionJ Lab Precis Med202162210.21037/jlpm-20-98 RosensonRSBakerSBanachMBorowKMBraunLTBruckertEOptimizing cholesterol treatment in patients with muscle complaintsJ Am Coll Cardiol2017701290130110.1016/j.jacc.2017.07.75228859793 ZeiserRImmune modulatory effects of statinsImmunology201815469751:CAS:528:DC%2BC1cXivVyms7w%3D10.1111/imm.12902293927315904709 BikdeliBMadhavanMVGuptaAJimenezDBurtonJRDer NigoghossianCPharmacological agents targeting thromboinflammation in COVID-19: review and implications for future researchThromb Haemost.20201201004102410.1055/s-0040-1713152324735967516364 KozmaCMDicksonMPhillipsALMeleticheDMMedication possession ratio: Implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosisPatient Prefer Adherence2013750951610.2147/PPA.S40736238078403685450 ColantonioLDShannonEDOrrothKKZahaRJacksonEARosensonRSExterJMuesKEMuntnerPIschemic event rates in very-high-risk adultsJ Am Coll Cardiol2019742496250710.1016/j.jacc.2019.09.02531727288 ShinYHMinJJLeeJHKimEHKimGEKimMHThe effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat heartsHeart Vessels20173261862710.1007/s00380-016-0936-528013371 GiustinoGPinneySPLalaAReddyVYJohnston-CoxHAMechanickJICoronavirus and cardiovascular disease, myocardial injury, and arrhythmia: JACC focus seminarJ Am Coll Cardiol202076201120231:CAS:528:DC%2BB3cXitFymtLfN10.1016/j.jacc.2020.08.059330927377572122 HariyantoTIKurniawanAStatin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infectionDiabetes Metab Syndr2020141613161510.1016/j.dsx.2020.08.023328826437448951 KongFYeBLinLCaiXHuangWHuangZAtorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-kappab signaling in PMA-stimulated THP-1 monocytesBiomed Pharmacother2016821671721:CAS:528:DC%2BC28Xnslegsro%3D10.1016/j.biopha.2016.04.04327470352 ToturaALWhitmoreAAgnihothramSSchaferAKatzeMGHeiseMTToll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infectionmBio20156e00638006151:CAS:528:DC%2BC2MXhvVyms7bF10.1128/mBio.00638-15260155004447251 World Health Organization. WHO coronavirus disease (COVID-19) dashboard. https://covid19.who.int/. Accessed 14 Sept 2021. ButtJHGerdsTASchouMKragholmKPhelpsMHavers-BorgersenEAssociation between statin use and outcomes in patients with coronavirus disease 2019 (covid-19): a nationwide cohort studyBMJ Open202010e04442110.1136/bmjopen-2020-04442133277291 WimmerNJResnicFSMauriLMathenyMEYehRWComparison of transradial versus transfemoral percutaneous coronary intervention in routine practice: evidence for the importance of “falsification hypotheses” in observational studies of comparative effectivenessJ Am Coll Cardiol2013622147214810.1016/j.jacc.2013.07.03623954334 VandermeerMLThomasARKamimotoLReingoldAGershmanKMeekJAssociation between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate studyJ Infect Dis201220513191:CAS:528:DC%2BC3MXhs12ht7%2FE10.1093/infdis/jir69522170954 KowCSHasanSSMeta-analysis of effect of statins in patients with covid-19Am J Cardiol20201341531551:CAS:528:DC%2BB3cXhslKhtLzO10.1016/j.amjcard.2020.08.004328913997419280 DanielsLBSitapatiAMZhangJZouJBuiQMRenJRelation of statin use prior to admission to severity and recovery among COVID-19 inpatientsAm J Cardiol20201361491551:CAS:528:DC%2BB3cXhvFegtb%2FO10.1016/j.amjcard.2020.09.012329468597492151 PinneySPGiustinoGHalperinJLMechanickJINeibartEOlinJWCoronavirus historical perspective, disease mechanisms, and clinical outcomes: JACC focus seminarJ Am Coll Cardiol202076199920101:CAS:528:DC%2BB3cXitFymtLfP10.1016/j.jacc.2020.08.058330927367571970 ZhangXJQinJJChengXShenLZhaoYCYuanYIn-hospital use of statins is associated with a reduced risk of mortality among individuals with covid-19Cell Metab202032176187 e1741:CAS:528:DC%2BB3cXht1ymsrzI10.1016/j.cmet.2020.06.015325926577311917 OesterleALaufsULiaoJKPleiotropic effects of statins on the cardiovascular systemCirc Res20171202292431:CAS:528:DC%2BC2sXjsFyltQ%3D%3D10.1161/CIRCRESAHA.116.308537280577955467317 McAuleyDFLaffeyJGO'KaneCMPerkinsGDMullanBTrinderTJSimvastatin in the acute respiratory distress syndromeN Engl J Med20143711695170310.1056/NEJMoa140328525268516 RidkerPMDanielsonEFonsecaFAGenestJGottoAMJrKasteleinJJRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med2008359219522071:CAS:528:DC%2BD1cXhtl2gurnL10.1056/NEJMoa080764618997196 HoffmannMKleine-WeberHSchroederSKrugerNHerrlerTErichsenSSars-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitorCell.2020181271280 e2781:CAS:528:DC%2BB3cXktl2qtb8%3D10.1016/j.cell.2020.02.052321426517102627 LiWMooreMJVasilievaNSuiJWongSKBerneMAAngiotensin-converting enzyme 2 is a functional receptor for the sars coronavirusNature20034264504541:CAS:528:DC%2BD3sXpt1GlsLs%3D10.1038/nature02145146473847095016 SaeedOCastagnaFAgalliuIXueXPatelSRRochlaniYStatin use and in-hospital mortality in patients with diabetes mellitus and covid-19J Am Heart Assoc20209e0184751:CAS:528:DC%2BB3MXmt12msLo%3D10.1161/JAHA.120.018475330924467955378 PrasadVJenaABPrespecified falsification end points: can they validate true observational associations?JAMA20133092412421:CAS:528:DC%2BC3sXht1Kisb8%3D10.1001/jama.2012.9686723321761 FrostFJPetersenHTollestrupKSkipperBInfluenza and COPD mortality protection as pleiotropic, dose-dependent effects of statinsChest2007131100610121:CAS:528:DC%2BD2sXltFOjtL8%3D10.1378/chest.06-199717426203 SikkaRXiaFAubertREEstimating medication persistency using administrative claims dataAm J Manag Care20051144945716044982 YuanSStatins may decrease the fatality rate of middle east respiratory syndrome infectionmBio20156e011201:CAS:528:DC%2BC28Xps1Cjsrk%3D10.1128/mBio.01120-15262657204542194 P Lohia (7263_CR18) 2021; 15 FJ Frost (7263_CR39) 2007; 131 7263_CR1 V Prasad (7263_CR28) 2013; 309 SP Pinney (7263_CR2) 2020; 76 F Zhou (7263_CR35) 2020; 395 S Shi (7263_CR5) 2020; 5 CS Kow (7263_CR22) 2020; 134 M Hoffmann (7263_CR11) 2020; 181 JH Butt (7263_CR23) 2020; 10 XJ Zhang (7263_CR21) 2020; 32 LD Colantonio (7263_CR6) 2019; 74 TI Hariyanto (7263_CR31) 2020; 14 PM Ridker (7263_CR8) 2008; 359 J Yang (7263_CR34) 2020; 94 V Roccaforte (7263_CR42) 2021; 6 B Bikdeli (7263_CR7) 2020; 120 K Tikoo (7263_CR13) 2015; 93 O Saeed (7263_CR20) 2020; 9 PK Bhatraju (7263_CR4) 2020; 382 F Kong (7263_CR10) 2016; 82 LB Daniels (7263_CR19) 2021; 16 R Sikka (7263_CR27) 2005; 11 S Yuan (7263_CR37) 2015; 6 G Giustino (7263_CR3) 2020; 76 A Oesterle (7263_CR9) 2017; 120 RS Rosenson (7263_CR15) 2017; 70 A Gupta (7263_CR17) 2021; 12 TI Hariyanto (7263_CR32) 2021; 31 YH Shin (7263_CR12) 2017; 32 D Choi (7263_CR25) 2020; 10 DF McAuley (7263_CR40) 2014; 371 W Li (7263_CR14) 2003; 426 A De Spiegeleer (7263_CR24) 2020; 21 7263_CR33 CM Kozma (7263_CR26) 2013; 7 TK Oh (7263_CR30) 2021; 11 AL Totura (7263_CR38) 2015; 6 NJ Wimmer (7263_CR29) 2013; 62 LB Daniels (7263_CR16) 2020; 136 R Zeiser (7263_CR36) 2018; 154 ML Vandermeer (7263_CR41) 2012; 205 |
References_xml | – volume: 134 start-page: 153 year: 2020 ident: 7263_CR22 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2020.08.004 contributor: fullname: CS Kow – volume: 9 start-page: e018475 year: 2020 ident: 7263_CR20 publication-title: J Am Heart Assoc doi: 10.1161/JAHA.120.018475 contributor: fullname: O Saeed – volume: 136 start-page: 149 year: 2020 ident: 7263_CR16 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2020.09.012 contributor: fullname: LB Daniels – volume: 62 start-page: 2147 year: 2013 ident: 7263_CR29 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2013.07.036 contributor: fullname: NJ Wimmer – volume: 120 start-page: 1004 year: 2020 ident: 7263_CR7 publication-title: Thromb Haemost. doi: 10.1055/s-0040-1713152 contributor: fullname: B Bikdeli – volume: 154 start-page: 69 year: 2018 ident: 7263_CR36 publication-title: Immunology doi: 10.1111/imm.12902 contributor: fullname: R Zeiser – volume: 131 start-page: 1006 year: 2007 ident: 7263_CR39 publication-title: Chest doi: 10.1378/chest.06-1997 contributor: fullname: FJ Frost – volume: 371 start-page: 1695 year: 2014 ident: 7263_CR40 publication-title: N Engl J Med doi: 10.1056/NEJMoa1403285 contributor: fullname: DF McAuley – volume: 11 start-page: 116 issue: 2 year: 2021 ident: 7263_CR30 publication-title: J Pers Med doi: 10.3390/jpm11020116 contributor: fullname: TK Oh – volume: 14 start-page: 1613 year: 2020 ident: 7263_CR31 publication-title: Diabetes Metab Syndr doi: 10.1016/j.dsx.2020.08.023 contributor: fullname: TI Hariyanto – volume: 309 start-page: 241 year: 2013 ident: 7263_CR28 publication-title: JAMA doi: 10.1001/jama.2012.96867 contributor: fullname: V Prasad – volume: 76 start-page: 1999 year: 2020 ident: 7263_CR2 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2020.08.058 contributor: fullname: SP Pinney – volume: 12 start-page: 1325 year: 2021 ident: 7263_CR17 publication-title: Nat Commun doi: 10.1038/s41467-021-21553-1 contributor: fullname: A Gupta – volume: 16 start-page: e0254635 year: 2021 ident: 7263_CR19 publication-title: PLoS One. doi: 10.1371/journal.pone.0254635 contributor: fullname: LB Daniels – volume: 426 start-page: 450 year: 2003 ident: 7263_CR14 publication-title: Nature doi: 10.1038/nature02145 contributor: fullname: W Li – volume: 11 start-page: 449 year: 2005 ident: 7263_CR27 publication-title: Am J Manag Care contributor: fullname: R Sikka – volume: 382 start-page: 2012 year: 2020 ident: 7263_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa2004500 contributor: fullname: PK Bhatraju – volume: 181 start-page: 271 year: 2020 ident: 7263_CR11 publication-title: Cell. doi: 10.1016/j.cell.2020.02.052 contributor: fullname: M Hoffmann – volume: 359 start-page: 2195 year: 2008 ident: 7263_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMoa0807646 contributor: fullname: PM Ridker – volume: 10 start-page: 19991 year: 2020 ident: 7263_CR25 publication-title: Sci Rep doi: 10.1038/s41598-020-77131-w contributor: fullname: D Choi – volume: 6 start-page: e01120 year: 2015 ident: 7263_CR37 publication-title: mBio doi: 10.1128/mBio.01120-15 contributor: fullname: S Yuan – volume: 205 start-page: 13 year: 2012 ident: 7263_CR41 publication-title: J Infect Dis doi: 10.1093/infdis/jir695 contributor: fullname: ML Vandermeer – volume: 93 start-page: 343 year: 2015 ident: 7263_CR13 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2014.11.013 contributor: fullname: K Tikoo – volume: 10 start-page: e044421 year: 2020 ident: 7263_CR23 publication-title: BMJ Open doi: 10.1136/bmjopen-2020-044421 contributor: fullname: JH Butt – volume: 70 start-page: 1290 year: 2017 ident: 7263_CR15 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2017.07.752 contributor: fullname: RS Rosenson – volume: 6 start-page: 2 year: 2021 ident: 7263_CR42 publication-title: J Lab Precis Med doi: 10.21037/jlpm-20-98 contributor: fullname: V Roccaforte – volume: 5 start-page: 802 year: 2020 ident: 7263_CR5 publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2020.0950 contributor: fullname: S Shi – volume: 15 start-page: 451 year: 2021 ident: 7263_CR18 publication-title: J Clin Lipidol doi: 10.1016/j.jacl.2021.03.002 contributor: fullname: P Lohia – volume: 120 start-page: 229 year: 2017 ident: 7263_CR9 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.116.308537 contributor: fullname: A Oesterle – volume: 82 start-page: 167 year: 2016 ident: 7263_CR10 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2016.04.043 contributor: fullname: F Kong – volume: 32 start-page: 618 year: 2017 ident: 7263_CR12 publication-title: Heart Vessels doi: 10.1007/s00380-016-0936-5 contributor: fullname: YH Shin – volume: 21 start-page: 909 year: 2020 ident: 7263_CR24 publication-title: J Am Med Dir Assoc doi: 10.1016/j.jamda.2020.06.018 contributor: fullname: A De Spiegeleer – volume: 32 start-page: 176 year: 2020 ident: 7263_CR21 publication-title: Cell Metab doi: 10.1016/j.cmet.2020.06.015 contributor: fullname: XJ Zhang – volume: 7 start-page: 509 year: 2013 ident: 7263_CR26 publication-title: Patient Prefer Adherence doi: 10.2147/PPA.S40736 contributor: fullname: CM Kozma – volume: 76 start-page: 2011 year: 2020 ident: 7263_CR3 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2020.08.059 contributor: fullname: G Giustino – volume: 74 start-page: 2496 year: 2019 ident: 7263_CR6 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2019.09.025 contributor: fullname: LD Colantonio – volume: 31 start-page: 1662 year: 2021 ident: 7263_CR32 publication-title: Nutr Metab Cardiovasc Dis doi: 10.1016/j.numecd.2021.02.020 contributor: fullname: TI Hariyanto – volume: 6 start-page: e00638 year: 2015 ident: 7263_CR38 publication-title: mBio doi: 10.1128/mBio.00638-15 contributor: fullname: AL Totura – volume: 94 start-page: 91 year: 2020 ident: 7263_CR34 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2020.03.017 contributor: fullname: J Yang – volume: 395 start-page: 1054 year: 2020 ident: 7263_CR35 publication-title: Lancet doi: 10.1016/S0140-6736(20)30566-3 contributor: fullname: F Zhou – ident: 7263_CR1 – ident: 7263_CR33 doi: 10.1136/postgradmedj-2020-139172 |
SSID | ssj0007998 |
Score | 2.4532695 |
Snippet | Purpose
COVID-19 is characterized by dysfunctional immune responses and metabolic derangements, which in some, lead to multi-organ failure and death. Statins... PurposeCOVID-19 is characterized by dysfunctional immune responses and metabolic derangements, which in some, lead to multi-organ failure and death. Statins... PURPOSECOVID-19 is characterized by dysfunctional immune responses and metabolic derangements, which in some, lead to multi-organ failure and death. Statins... |
SourceID | pubmedcentral proquest crossref springer |
SourceType | Open Access Repository Aggregation Database Publisher |
StartPage | 1165 |
SubjectTerms | Cardiology Cardiovascular disease Cardiovascular diseases Clinical trials Comorbidity Coronary artery disease Coronary vessels Coronaviruses COVID-19 Death Health hazards Heart diseases Hospitalization Immune response Immunomodulation Lipids Medicine Medicine & Public Health Mortality Original Original Article Patients Risk management Statins Statistical models Subgroups Vein & artery diseases Viral diseases |
SummonAdditionalLinks | – databaseName: ProQuest_Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwEB1BkRAXRAuI0BYZCfXCWvgzjk-oKq0KqLCHFu0tip1Y7SVb2O1h_33HXmejrURvkezIjsfxzHhm3gP4VFW8M7IJFNWbo6qRljphNXWGieADc1Wie7v4VZ5fqR8zPcsXboucVjmciemgbuc-3pF_QTWr8cAVvPx6-5dG1qgYXc0UGk_hGRdoTOB-NrONw8WMTVy4zMYqYcHKXDSTS-e0NjQmKDAjSknFtmIarc2HuZIPAqZJD529gpfZgCTHa4nvwpOu34PnFzlEvgdH0zUY9WpCLsfaqsWEHJHpCFO9eg0_TyN6BHYk80CizXnT5zdWBB-na8DVBYk3tWSgFyERbDcmzvYErV1y8vvP92-U2zdwdXZ6eXJOM7UC9egwLqnioXQ8WIfaiSvny8AaL6QNre2UMya0vhFSCW-cNo4F3lneStsG3XBlUMW_hZ1-3nfvgFROtaErE3O6iji3TvmW-cq1SnZozxTweVjX-naNoFGPWMlRCjVKoU5SqEUBB8PS1_lvWtSj7Av4uGnGz43Bjabv5nfYR6ObIGNdcAFmS2SbUSOS9nZLf3OdELUrhX6t1AVMBuGOg_9_ru8fn-s-vBCxViLlvhzAzvLfXXeIFszSfUjb9B7V2uxe priority: 102 providerName: ProQuest |
Title | Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19 |
URI | https://link.springer.com/article/10.1007/s10557-021-07263-2 https://www.proquest.com/docview/2735413216 https://search.proquest.com/docview/2572934226 https://pubmed.ncbi.nlm.nih.gov/PMC8440735 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwED7BJiFeEGxDBEblSdNeqKX4Vxw_ltGxMW1U04rKUxQntuhLimj30P-es5s0dIIHnhLJTpz4HN93ubvvAE7znDktSk9RvVkqS2Go5UZRq1PuK5_aPJZ7u7nNLqfyy0zN-jzuGOzeeSTjRv1HrptSmoaIglTzTFDcd_cDeAhLecpH2-1Xm1gANzUhNZinWZsp8_d77GqjHmI-DpB85CWNyufiJbxoUSMZbcT8Cp645gCe3bR-8QM4m2wYqNdDct8nVC2H5IxMem7q9SFcjwNlBHYkC08C0Jw37RVrgqeTDcvqkoTfs6SrKUICw26Ilm0IQlxy_vXb1SfKzBFML8b355e0radAK7QSV1Qyn1nmjUWVxKStMp-WFRfG18ZJq7Wvq5ILySttlbapZ86wWpjaq5JJjXr9New1i8a9AZJbWXuXxXLpMpDbWlnVaZXbWgqHICaBD928Fj83tBlFT5AcpFCgFIoohYIncNxNfdF-QssCcZVCDctZlsDJthlfN3g0ysYtHrCPQttAhGTgBPSOyLajBvrs3ZZm_iPSaOcSjVmhEhh2wu0H__ezvv2_7u_gOQ8JEzEA5hj2Vr8e3HuEMSs7gKd6pgewP_r8_XqMx4_j28ndIC7m30Pt7QA |
link.rule.ids | 230,315,786,790,891,12083,21416,27957,27958,31754,31755,33779,33780,41116,41558,42185,42627,43345,43840,52146,52269,74102,74659 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFH8anTR2QWwDLWwwI6FdqEX8FccnBKNT99FSoQ7tFsWOre2SjrU79L_HTp1GnQS3SE5kx7_kffi993sAn_KcWMlKh71605iXTGFNlcBaptQZl-q8afc2GmfDG355K27jgds8plW2MrER1NXMhDPyL17NCi9wKcm-PvzBoWtUiK7GFhovYJsz76r0YPv7YDz5tZbFUjXdcFMV6oRpmsWymVg8J4TEIUUhlTRjmG6qps7efJ4t-Sxk2mii89fwKpqQ6NsK8z3YsvU-7IxikHwfTicrOuplH0276qp5H52iSUdUvTyAq0Hgj_A3oplDweq8r-MTS-QvJyvK1TkKZ7WobTCCAt1uSJ2tkbd30dnP3xc_MFFv4OZ8MD0b4thcARvvMi4wJy7TxCnt9RPh2mQuLQ1lylXKci2lq0xJGadGaiF16ohVpGKqcqIkXHol_xZ69ay2h4ByzStns6Z3Og9Mt5qbKjW5rjiz3qJJ4HO7r8XDikOj6NiSAwqFR6FoUChoAsft1hfxf5oXHfoJfFwP-9cN4Y2ytrMnf4_wjgILlcEJyA3I1rMGLu3Nkfr-ruHUzrn3bJlIoN-C203-77W--_9aT-DlcDq6Lq4vxldHsEtD5USTCXMMvcXjk33v7ZmF_hA_2r8prPCz |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BK1VcqlJABAoYCfXCWo1fcXxC0O6qpXSJUIt6i2InFr1kW3Z72H_fcdbZaCvBLZId2fFM5uGZ-QbgU56zRovKU1RvlspKGGq5UdTqlHvnU5t37d4uptnplfx-ra5j_tM8plX2MrET1PXMhTvyI1SzCgUuZ9mRj2kRxcnky-0dDR2kQqQ1ttN4CttaZgo5fPvbeFr8WstlbbrOuKkJNcM8zWIJTSykU0rTkK6Qap4JyjfV1GB7Ps6cfBQ-7bTSZA92ozlJvq7o_xyeNO0-7FzEgPk-HBYraOrliFwOlVbzETkkxQBavXwB5-OAJYETycyTYIHetPGNJcHHYgW_Oifh3pb0zUZIgN4NabQtQduXHP_8fXZCmXkJV5Px5fEpjY0WqEP3cUEl85ll3ljUVUxal_m0clwYX5tGWq197SouJHfaKm1TzxrDamFqryomNSr8V7DVztrmNZDcyto3WddHXQbUWytdnbrc1lI0aN0k8Lk_1_J2hadRDsjJgQolUqHsqFDyBA76oy_jvzUvB05I4ON6GD83hDqqtpnd4xyFToMIVcIJ6A2SrVcNuNqbI-3Nnw5fO5fo5QqVwKgn7rD4v_f65v97_QA7yK_lj7Pp-Vt4xkMRRZcUcwBbi7_3zTs0bRb2feTZB6eH9PA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+Statin+Therapy+in+Patients+with+Hospital+Admission+for+COVID-19&rft.jtitle=Cardiovascular+drugs+and+therapy&rft.au=Choi%2C+Daein&rft.au=Chen%2C+Qinzhong&rft.au=Goonewardena%2C+Sascha+N&rft.au=Pacheco%2C+Hannah&rft.date=2022-12-01&rft.eissn=1573-7241&rft.volume=36&rft.issue=6&rft.spage=1165&rft.epage=1173&rft_id=info:doi/10.1007%2Fs10557-021-07263-2&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0920-3206&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0920-3206&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0920-3206&client=summon |